Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
6(85.7%)
Phase 2
1(14.3%)
7Total
Phase 1(6)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT06964061Phase 1Active Not Recruiting

Evaluate Efficacy, Safety, Tolerability and Biodegradation of PA5346 Ocular Implant in Patients With Open-Angle Glaucoma or Ocular Hypertension

Role: lead

NCT04060758Phase 1Completed

Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma

Role: lead

NCT06964191Phase 2Recruiting

Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension

Role: lead

NCT05333419Phase 1Completed

Study of a Latanoprost Ocular Implant for Treatment of Open Angle Glaucoma or Ocular Hypertension.

Role: lead

NCT05441930Phase 1Withdrawn

A Study of Levofloxacin Ocular Implant in Patients Undergoing Routine Bilateral Cataract Surgery

Role: lead

NCT04682288Phase 1Completed

Levofloxacin Ocular Implant for Ocular Surgery

Role: lead

NCT03604328Phase 1Completed

Safety and Tolerability of a Prostaglandin Ocular Implant for Treatment of Open Angle Glaucoma

Role: lead

All 7 trials loaded